In case you missed any, under is a recap of each episode of OncLive On Air® that aired in June 2024. Take a look at our podcast web page for a full episode lineup and to remain updated with all the newest releases!
Lenz Discusses the Prognostic and Predictive Worth of HER2 Gene Expression in KRAS Wild-Sort mCRC
In this unique interview, a part of an OncClub sequence, Heinz-Josef Lenz, MD, FACP, of the College of Southern California (USC) Keck Faculty of Medication in Los Angeles, highlighted information gaps concerning the function of HER2 expression in metastatic colorectal most cancers (mCRC), the connection between HER2 expression and responses with bevacizumab (Avastin)– vs cetuximab (Erbitux)–based mostly regimens, and the potential for HER2 expression to information remedy choices for sufferers with mCRC.
“RNA generally is a extra quantitative measure for higher understanding HER2 expression in tumors, [accounting for] the constraints of immunohistochemistry,” Lenz mentioned. “With this, I hope that we now have a brand new understanding [of how] to make use of HER2 as a predictive and prognostic marker, but additionally open [a path] to combine extra RNA know-how into molecular diagnostics.”
In the inaugural episode of OncLive On Air’s partnership with Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana College Well being in Indianapolis and Karine Tawagi, MD, of the College of Illinois in Chicago, mentioned prime takeaways from the first outcomes of the part 3 LAURA trial (NCT03521154), which evaluated osimertinib (Tagrisso) following chemoradiation in sufferers with stage III, unresectable, EGFR-mutated non–small cell lung most cancers (NSCLC).
“It’s apply altering that now suppliers can provide osimertinib to those high-risk, unresectable, stage III [patients], relatively than durvalumab [Imfinzi],” Tawagi famous. “It’s additionally nice that on this trial, they did permit crossover as a result of in any other case some sufferers might haven’t made it to the following line of remedy.”
“Staging for NSCLC is extraordinarily detailed, however it’s additionally closely examined on our board [exams],” Armstrong emphasised to oncology trainees. “I positively bear in mind we had no less than 3 to 4 stage III NSCLC questions on our boards day, so undergo, evaluate these, discover a manner…to memorize the essential particulars of it, so while you go into check day, you already know: Stage I, II, or III, and is it resectable stage III or unresectable stage III? They are going to check you on these closely.”
In this episode of How This Is Constructing Me, host D. Ross Camidge, MD, PhD, sat down with Chaplain Rhonda Cooper, the previous major chaplain of the Johns Hopkins Sidney Kimmel Most cancers Middle in Baltimore, Maryland, to debate Cooper’s profession as a chaplain, the main target of and findings from her writing and analysis about hospital chaplaincy, and the significance of addressing particular person affected person wants and luxury ranges when offering non secular care.
“The concept of speaking to a chaplain appealed to me as a result of I feel you don’t get the airtime,” Camidge famous. “You’re there, and you’re a central a part of the workforce, however some persons are not realizing that there’s an individual behind that.”
“We attempt to be for that affected person or that care companion or employees member what they want us to be,” Cooper emphasised concerning the function of chaplains.
In this unique dialog, Ari Rosenberg, MD, of the College of Chicago Medication in Illinois, highlighted standard-of-care remedy methods for sufferers with nasopharyngeal most cancers, the evolving function of toripalimab-tpzi (Loqtorzi) on this remedy enviornment, and the way future advances in nasopharyngeal most cancers analysis and administration might positively have an effect on the general head and neck most cancers remedy paradigm.
“Since we’ve seen such a formidable combinatorial impact of toripalimab as an immune checkpoint inhibitor together with gemcitabine and platinum-based chemotherapy within the recurrent metastatic setting, the pure development from that’s incorporating toripalimab, or different immune checkpoint inhibitors, into the locoregionally superior paradigm for nasopharyngeal carcinoma,” Rosenberg emphasised.
In this interview, Karen L. Reckamp, MD, of Cedars-Sinai Medical Middle in Los Angeles, California, explains the aim and design components of pragmatic medical trials, the pragmatic objectives of the part 3 S2302 Pragmatica-Lung trial (NCT05633602), and the way oncology researchers could make medical trials extra pragmatic.
“It is a second the place we need to degree the taking part in discipline and improve illustration in our trials,” Reckamp emphasised. “To try this, we have to make trials much less advanced when it’s acceptable and attempt to reply easy questions along with the advanced molecular and biologic questions we now have.”
In this unique interview, Mark Agulnik, MD, of the USC Keck Faculty of Medication, highlighted notable updates within the administration of gastrointestinal stromal tumor (GIST) forward of GIST Consciousness Day on July 13, together with illness components that may drive customized remedy decision-making; how ripretinib (Qinlock) has influenced the remedy paradigm; and the way ongoing analysis inside the GIST realm might speed up the evolution of the remedy of sufferers with this illness.
“At the moment, [the GIST treatment paradigm] is a lot better positioned than [it has been] up to now a number of years,” Agulnik emphasised. “There are a selection of research which can be ongoing, and my suggestion all the time could be to see whether or not there’s a medical trial within the space of the place you reside, so sufferers might be diverted to these trials. The advantage of that, then, is that your complete neighborhood will get entry to medicine as soon as they arrive to market.”
In this dialog, Martin F. Dietrich, MD, PhD, of Most cancers Care Facilities of Brevard, The US Oncology Community, in House Coast, Florida, and the College of Central Florida Faculty of Medication in Orlando; and Michelle Shiller, DO, of Baylor Scott & White Well being in Dallas, Texas, and PathGroup, element the significance of reflex testing in cancers akin to lung most cancers, how the sort of testing might be integrated in oncology apply, and the importance of collaboration between medical oncologists and pathologists to facilitate profitable reflex testing to enhance affected person outcomes.
“It will be a missed alternative to not benefit from the experience that our colleagues in molecular pathology carry to the desk,” Dietrick emphasised. “For us, it’s necessary to have a transparent interpretation. I see in my apply a good variety of second opinions, so having first-hand perception into the interpretation of a few of these outcomes, how our colleagues are doing it, it’s necessary to construct a community of help that assists within the interpretation and implementation of those testing outcomes.”
“As a pathologist, I strongly encourage my pathology colleagues to familiarize themselves with each facet, to dig into the Nationwide Complete Most cancers Community pointers, and assist to guide the dialog from a testing perspective, because the oncologists have so many different variables to be contemplating with their sufferers,” Shiller added.
